CAR-based cell therapies are revolutionizing the treatment of tumors, especially hematological ones (image: University of Texas/MD Anderson Cancer Center)
Immunology
New strategies boost effectiveness of CAR-NK therapy against cancerA study by FAPESP-supported center used the NK-92 cell line to test new chimeric antigen receptor (CAR) models. Tests demonstrated an increased ability of the cells to destroy tumors.
Immunology
New strategies boost effectiveness of CAR-NK therapy against cancerA study by FAPESP-supported center used the NK-92 cell line to test new chimeric antigen receptor (CAR) models. Tests demonstrated an increased ability of the cells to destroy tumors.
CAR-based cell therapies are revolutionizing the treatment of tumors, especially hematological ones (image: University of Texas/MD Anderson Cancer Center)
Agência FAPESP – Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12. The tests showed that these components helped make the cells “ready to attack,” thereby increasing their ability to destroy tumors. The results were published in the journal Frontiers in Immunology.
The CTC is one of the Research, Innovation, and Dissemination Centers (RIDCs) supported by FAPESP. It is based at the Ribeirão Preto Blood Center and is linked to the general and teaching hospital (“Hospital das Clínicas”) of the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP).
CAR-based cell therapies are revolutionizing cancer treatment, especially for hematological tumors. However, although it is already known which components work best in CAR-T cells, many questions remain about which intracellular signals make CAR-NK cells more effective.
The CTC’s research demonstrates that combining optimized co-stimulation with reversible pharmacological control can enhance the potency and efficiency of CAR-NK therapies, paving the way for new generations of cell therapies.
The research also evaluated using the drug dasatinib temporarily to control the activation of these cells. According to the Ribeirão Preto Blood Center Press Office, in animal models, CAR-NK cells with 2B4-DAP12, pretreated with dasatinib, showed better tumor control compared to traditional versions.
Those interested in learning more about the research can watch a video on the Ribeirão Preto Blood Center’s YouTube channel.
The article “2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity” can be read at frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1675877.
Republish
Republish
The Agency FAPESP licenses news via Creative Commons (CC-BY-NC-ND) so that they can be republished free of charge and in a simple way by other digital or printed vehicles. Agência FAPESP must be credited as the source of the content being republished and the name of the reporter (if any) must be attributed. Using the HMTL button below allows compliance with these rules, detailed in Digital Republishing Policy FAPESP.